Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma CorpfiledCriticalMitsubishi Tanabe Pharma Corp
Publication of HN2009001135ApublicationCriticalpatent/HN2009001135A/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
UNA FORMA CRISTALINA NOVEDOSA DEL HEMIHIDRATO DE 1-(B-D GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL] BENCENO, QUE TIENE CARACTERISTICAS FAVORABLES, SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X DE POLVO Y/O POR SU ESPECTRO INFRARROJO FIG.1 DIFRACCION DE RAYOS X- DE POLVO
HN2009001135A2006-12-042009-06-04Forma cristalinas del hemihidrato de 1-(b-d-glucopiranosil)- 4-metil,3-{5-(4-fluorofenil)-2-tienilmetil} benceno
HN2009001135A
(es)
Formas solidas de 1-metil-5-(2-(5-(trifluoro-metil)-1h-imidazol-2-il)-piridin-4-iloxi)-n-(4-(trifluoro-metil)-fenil)-1h-benzo-[d]-imidazol-2-amina con actividad inhibidora de cinasa raf y una composicion farmaceutica que las comprende.